Biotechs as Late-Stage Licensees
Executive Summary
It was not so long ago that a large pharmaceutical company would have been extremely skeptical of selling a late-stage or marketed drug to a biotech. What has changed?You may also be interested in...
FDA Commissioner Nominee Hahn Advances To Full Senate, Despite Some Dems’ Reservations
Stephen Hahn, the Trump administration’s nominee to lead the US FDA, has been approved by the Senate Health, Education, Labor and Pensions (HELP) Committee, with some “no votes” from Democratic senators in leadership positions, and is expected to be considered by the full Senate this week.
FDA Holding February Public Meeting On Using AI In Radiology
The US agency will host a two-day meeting to discuss the evolution of artificial intelligence technology used to analyze radiological images when diagnosing patients and in advising radiologists to take optimal pictures. The takeaways from the meeting will be used by the FDA to help it develop its thinking on how to regulate such technology.
Merck & Co. Joins Competitive BTK Research Space With $2.7bn ArQule Buy
ArQule's lead candidate, ARQ 531, is a novel BTK inhibitor in Phase II development that could work in patients with B-cell malignancies resistant to existing BTK inhibitors like Imbruvica.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: